Literature DB >> 22954411

Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: implications for planning 90Y radioembolization?

M C Burgmans1, C W Too, Y H Kao, A S W Goh, P K H Chow, B S Tan, K H Tay, R H G Lo.   

Abstract

PURPOSE: To compare the hepatic falciform artery (HFA) detection rates of digital subtraction angiography (DSA), computed tomography hepatic arteriography (CTHA) and 99mTc-macroaggregated albumin (99mTc-MAA) single photon emission computed tomography with integrated CT (SPECT/CT) and to correlate HFA patency with complication rates of yttrium-90 (90Y) radioembolization.
MATERIAL AND METHODS: From August 2008 to November 2010, 79 patients (range 23-83 years, mean 62.3 years; 67 male) underwent pre-treatment DSA, CTHA and 99mTc-MAA scintigraphy (planar/SPECT/CT) to assess suitability for radioembolization with 90Y resin microspheres. Thirty-seven patients were excluded from the study, because CTHA was performed with a catheter position that did not result in opacification of the liver parenchyma adjacent to the falciform ligament. DSA, CTHA and 99mTc-MAA SPECT/CT images and medical records were retrospectively reviewed.
RESULTS: A patent HFA was detected in 22 of 42 patients (52.3%). The HFA detection rates of DSA, CTHA and 99mTc-MAA SPECT/CT were 11.9%, 52.3% and 13.3%, respectively (p<0.0001). An origin from the segment 4 artery was seen in 51.7% of HFAs. Prophylactic HFA coil-embolization prior to 90Y microspheres infusion was performed in 2 patients. Of the patients who underwent radioembolization with a patent HFA, none developed supra-umbilical radiation dermatitis. One patient experienced epigastric pain attributed to post-embolization syndrome and was managed conservatively.
CONCLUSION: The HFA detection rate of CTHA is superior to that of DSA and 99mTc-MAA SPECT/CT. Complications related to non-target radiation of the HFA vascular territory rarely occur, even in patients undergoing radioembolization with a patent HFA.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22954411     DOI: 10.1016/j.ejrad.2012.08.007

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

Review 1.  Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry.

Authors:  Aaron K T Tong; Yung Hsiang Kao; Chow Wei Too; Kenneth F W Chin; David C E Ng; Pierce K H Chow
Journal:  Br J Radiol       Date:  2016-03-24       Impact factor: 3.039

Review 2.  The role of SPECT/CT in radioembolization of liver tumours.

Authors:  Hojjat Ahmadzadehfar; Heying Duan; Alexander R Haug; Stephan Walrand; Martha Hoffmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-18       Impact factor: 9.236

Review 3.  Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts.

Authors:  Christopher Molvar; Robert Lewandowski
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

Review 4.  The Role of Catheter-Directed CT-Angiography in Radioembolisation.

Authors:  Kun Da Zhuang; Aaron Kian-Ti Tong; David Chee Eng Ng; Kiang Hiong Tay
Journal:  Cardiovasc Intervent Radiol       Date:  2022-05-20       Impact factor: 2.740

5.  Selective internal radiation therapy of hepatic tumors: procedural implications of a patent hepatic falciform artery.

Authors:  Juliane Schelhorn; Judith Ertle; Joerg F Schlaak; Stefan Mueller; Andreas Bockisch; Thomas Schlosser; Thomas Lauenstein
Journal:  Springerplus       Date:  2014-10-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.